

- ablation." *Heart Rhythm* 2012; Nov 23. pii: S1547-5271(12)01340-9. doi: 10.1016/j.hrthm.2012.11.012. [Epub ahead of print].
23. Parvez B, Benjamin Shoemaker M, Muhammad R, et al. Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. *Heart Rhythm* 2013 Feb 18. pii: S1547-5271(13)00161-6. doi: 10.1016/j.hrthm.2013.02.018. [Epub ahead of print]
 24. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. *Lancet* 2010; 376:1312–1319.
 25. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. *Circulation* 2009; 119:2553–2560.
 26. Wallentin L, James S, Storey RF, et al; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. *Lancet* 2010; 376:1320–1328.
 27. Guzauskas GF, Hughes DA, Bradley SM, Veenstra DL. A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. *Clin Pharmacol Ther* 2012; 91:829–837.
 28. Crespin DJ, Federspiel JJ, Biddle AK, Jonas DE, Rossi JS. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. *Value Health* 2011; 14:483–491.
 29. Mega JL, Hochholzer W, Frelinger AL 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. *JAMA* 2011; 306:2221–2228.
 30. Xu H, Jiang M, Oetjens M, et al. Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. *J Am Med Inform Assoc* 2011; 18:387–391.
 31. Teng K, Eng C, Hess CA, et al. Building an innovative model for personalized healthcare. *Cleve Clin J Med* 2012; 79(suppl 1):S1–S9.
 32. Kaddurah-Daouk R, Baillie RA, Zhu H, et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. *PLoS One* 2011; 6:e25482.
 33. Bodi V, Sanchis J, Morales JM, et al. Metabolomic profile of human myocardial ischemia by nuclear magnetic resonance spectroscopy of peripheral blood serum: a translational study based on transient coronary occlusion models. *J Am Coll Cardiol* 2012; 59:1629–1641.
 34. Shah SH, Sun JL, Stevens RD, et al. Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. *Am Heart J* 2012; 163:844–850.e1.
-
ADDRESS: Patrick A. Gladding, MBChB, PhD, 26 Volcanic St., Mt. Eden, Auckland, New Zealand 1041; e-mail: patrickg@theranosticslab.com

CORRECTIONS

Emergency contraception

(NOVEMBER 2012)

Decimal points were misplaced in **TABLE 1** in the article by Dr. Pelin Batur, Emergency contraception: Separating fact from fiction. *Cleve Clin J Med* 2012; 79:771–776. The cor-

rect dose of levonorgestrel (Plan B One-Step, Next Choice, generic) is 1.5 mg orally $\times$ 1 or 0.75 mg orally $\times$ 2. The table has been corrected online.

Acute pancreatitis

(JUNE 2013)

Dr. Todd Baron's middle initial was omitted in his article, Managing severe acute pancreatitis. *Cleve Clin J Med* 2013; 80:354–359. His

full name is Todd H. Baron, MD. This information has been added online.